News | April 10, 2023
Thermo Fisher Scientific expands its capabilities in France
Bourgoin early development hub broadens offerings for oral solid dose formulations
Bourgoin early development hub broadens offerings for oral solid dose formulations
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
The new sterile filling line meets cGMP aseptic filling regulatory requirements
The company has announced net revenue of Rs. 639.8 crore for Q3 FY23 as compared to Rs. 562.08 crore in the corresponding period of the previous year
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
Subscribe To Our Newsletter & Stay Updated
